These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36038111)

  • 61. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
    Gottlieb CE; Mills AM; Cross JV; Ring KL
    Gynecol Oncol; 2017 Mar; 144(3):607-612. PubMed ID: 28065619
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.
    Qu H; Xia Y; Li X
    Curr Gene Ther; 2020; 20(4):313-320. PubMed ID: 32851960
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
    Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
    JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular and phenotypic characteristics influencing the degree of cytoreduction in high-grade serous ovarian carcinomas.
    Torkildsen CF; Thomsen LCV; Sande RK; Krakstad C; Stefansson I; Lamark EK; Knappskog S; Bjørge L
    Cancer Med; 2023 Jul; 12(13):14183-14195. PubMed ID: 37191035
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
    Zhang Q; Wang C; Cliby WA
    Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment-naïve patients: A single-center study.
    Nikas IP; Lee C; Song MJ; Kim B; Ryu HS
    Cancer Med; 2022 Jun; 11(11):2193-2203. PubMed ID: 35212471
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
    Li Y; Fei H; Lin Q; Liang F; You Y; Li M; Wu M; Qu Y; Li P; Yuan Y; Chen T; Jiang H
    Oncogene; 2021 Aug; 40(32):5131-5141. PubMed ID: 34211089
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis.
    Yang B; Li X; Zhang W; Fan J; Zhou Y; Li W; Yin J; Yang X; Guo E; Li X; Fu Y; Liu S; Hu D; Qin X; Dou Y; Xiao R; Lu F; Wang Z; Qin T; Wang W; Zhang Q; Li S; Ma D; Mills GB; Chen G; Sun C
    Cell Rep Med; 2022 Dec; 3(12):100856. PubMed ID: 36543113
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment.
    Vetter M; Stadlmann S; Bischof E; Georgescu Margarint EL; Schötzau A; Singer G; Heinzelmann-Schwarz V; Montavon C
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430718
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.
    Lawrenson K; Fonseca MAS; Liu AY; Segato Dezem F; Lee JM; Lin X; Corona RI; Abbasi F; Vavra KC; Dinh HQ; Gill NK; Seo JH; Coetzee S; Lin YG; Pejovic T; Mhawech-Fauceglia P; Rowat AC; Drapkin R; Karlan BY; Hazelett DJ; Freedman ML; Gayther SA; Noushmehr H
    Cell Rep; 2019 Dec; 29(11):3726-3735.e4. PubMed ID: 31825847
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
    Zhang P; He M; Zeng Y; Cai X
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer.
    Jin X; Du M; Wang Y; Wang Y; Lu Y; Xu C; Zhang X
    J Ovarian Res; 2022 Dec; 15(1):134. PubMed ID: 36564848
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
    Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
    Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
    [No Abstract]   [Full Text] [Related]  

  • 76. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ovarian cancer mutational processes drive site-specific immune evasion.
    Vázquez-García I; Uhlitz F; Ceglia N; Lim JLP; Wu M; Mohibullah N; Niyazov J; Ruiz AEB; Boehm KM; Bojilova V; Fong CJ; Funnell T; Grewal D; Havasov E; Leung S; Pasha A; Patel DM; Pourmaleki M; Rusk N; Shi H; Vanguri R; Williams MJ; Zhang AW; Broach V; Chi DS; Da Cruz Paula A; Gardner GJ; Kim SH; Lennon M; Long Roche K; Sonoda Y; Zivanovic O; Kundra R; Viale A; Derakhshan FN; Geneslaw L; Issa Bhaloo S; Maroldi A; Nunez R; Pareja F; Stylianou A; Vahdatinia M; Bykov Y; Grisham RN; Liu YL; Lakhman Y; Nikolovski I; Kelly D; Gao J; Schietinger A; Hollmann TJ; Bakhoum SF; Soslow RA; Ellenson LH; Abu-Rustum NR; Aghajanian C; Friedman CF; McPherson A; Weigelt B; Zamarin D; Shah SP
    Nature; 2022 Dec; 612(7941):778-786. PubMed ID: 36517593
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
    Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
    [No Abstract]   [Full Text] [Related]  

  • 79. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Single-cell RNA sequencing reveals the change in cytotoxic NK/T cells, epithelial cells and myeloid cells of the tumor microenvironment of high-grade serous ovarian carcinoma.
    Meng L; Sun S
    Discov Oncol; 2024 Sep; 15(1):417. PubMed ID: 39249551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.